TY - JOUR
T1 - Microbiota-gut brain axis involvement in neuropsychiatric disorders
AU - Iannone, Luigi Francesco
AU - Preda, Alberto
AU - Blottière, Hervé M.
AU - Clarke, Gerard
AU - Albani, Diego
AU - Belcastro, Vincenzo
AU - Carotenuto, Marco
AU - Cattaneo, Annamaria
AU - Citraro, Rita
AU - Ferraris, Cinzia
AU - Ronchi, Francesca
AU - Luongo, Gaia
AU - Santocchi, Elisa
AU - Guiducci, Letizia
AU - Baldelli, Pietro
AU - Iannetti, Paola
AU - Pedersen, Sigrid
AU - Petretto, Andrea
AU - Provasi, Stefania
AU - Selmer, Kaja
AU - Spalice, Alberto
AU - Tagliabue, Anna
AU - Verrotti, Alberto
AU - Segata, Nicola
AU - Zimmermann, Jakob
AU - Minetti, Carlo
AU - Mainardi, Paolo
AU - Giordano, Carmen
AU - Sisodiya, Sanjay
AU - Zara, Federico
AU - Russo, Emilio
AU - Striano, Pasquale
PY - 2019/10/3
Y1 - 2019/10/3
N2 - Introduction: The microbiota-gut brain (MGB) axis is the bidirectional communication between the intestinal microbiota and the brain. An increasing body of preclinical and clinical evidence has revealed that the gut microbial ecosystem can affect neuropsychiatric health. However, there is still a need of further studies to elucidate the complex gene–environment interactions and the role of the MGB axis in neuropsychiatric diseases, with the aim of identifying biomarkers and new therapeutic targets, to allow early diagnosis and improving treatments. Areas covered: To review the role of MGB axis in neuropsychiatric disorders, prediction and prevention of disease through exploitation, integration, and combination of data from existing gut microbiome/microbiota projects and appropriate other International ‘-Omics’ studies. The authors also evaluated the new technological advances to investigate and modulate, through nutritional and other interventions, the gut microbiota. Expert opinion: The clinical studies have documented an association between alterations in gut microbiota composition and/or function, whereas the preclinical studies support a role for the gut microbiota in impacting behaviors which are of relevance to psychiatry and other central nervous system (CNS) disorders. Targeting MGB axis could be an additional approach for treating CNS disorders and all conditions in which alterations of the gut microbiota are involved.
AB - Introduction: The microbiota-gut brain (MGB) axis is the bidirectional communication between the intestinal microbiota and the brain. An increasing body of preclinical and clinical evidence has revealed that the gut microbial ecosystem can affect neuropsychiatric health. However, there is still a need of further studies to elucidate the complex gene–environment interactions and the role of the MGB axis in neuropsychiatric diseases, with the aim of identifying biomarkers and new therapeutic targets, to allow early diagnosis and improving treatments. Areas covered: To review the role of MGB axis in neuropsychiatric disorders, prediction and prevention of disease through exploitation, integration, and combination of data from existing gut microbiome/microbiota projects and appropriate other International ‘-Omics’ studies. The authors also evaluated the new technological advances to investigate and modulate, through nutritional and other interventions, the gut microbiota. Expert opinion: The clinical studies have documented an association between alterations in gut microbiota composition and/or function, whereas the preclinical studies support a role for the gut microbiota in impacting behaviors which are of relevance to psychiatry and other central nervous system (CNS) disorders. Targeting MGB axis could be an additional approach for treating CNS disorders and all conditions in which alterations of the gut microbiota are involved.
KW - inflammation
KW - Ketogenic diet
KW - manipulating microbiota
KW - metabolomics
KW - microbiota-gut brain axis
KW - neuropsychiatric disorders
UR - http://www.scopus.com/inward/record.url?scp=85071718389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071718389&partnerID=8YFLogxK
U2 - 10.1080/14737175.2019.1638763
DO - 10.1080/14737175.2019.1638763
M3 - Review article
C2 - 31260640
AN - SCOPUS:85071718389
VL - 19
SP - 1037
EP - 1050
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
SN - 1473-7175
IS - 10
ER -